Attached files
| file | filename |
|---|---|
| EX-23.2 - EX-23.2 - Acer Therapeutics Inc. | d890540dex232.htm |
| EX-5.1 - EX-5.1 - Acer Therapeutics Inc. | d890540dex51.htm |
| S-1 - S-1 - Acer Therapeutics Inc. | d890540ds1.htm |
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
Acer Therapeutics Inc.
Newton, Massachusetts
We hereby consent to the incorporation by reference in the Prospectus constituting a part of this Registration Statement of our report dated March 18, 2020, relating to the consolidated financial statements of Acer Therapeutics Inc. appearing in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019. Our report contains an explanatory paragraph regarding the Company’s ability to continue as a going concern.
We also consent to the reference to us under the caption “Experts” in the Prospectus.
/s/ BDO USA, LLP
Boston, Massachusetts
May 12, 2020